COSM - Cosmos Holdings Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
3.1500
0.0000 (0.00%)
At close: 3:08PM EDT
Stock chart is not supported by your current browser
Previous Close 3.1500
Open 3.1500
Bid 0.0000 x 0
Ask 0.0000 x 0
Day's Range 3.1500 - 3.1500
52 Week Range 2.0300 - 7.4900
Volume 200
Avg. Volume 1,285
Market Cap 41.226M
Beta (3Y Monthly) 1.16
PE Ratio (TTM) N/A
EPS (TTM) -0.6330
Earnings Date Apr 23, 2019
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est N/A
Trade prices are not sourced from all markets
  • GlobeNewswire

    Cosmos Holdings, Inc. Completes $550,000 Debt-to-Equity Conversion at $7.50 Per Share

    CHICAGO, June 25, 2019 -- Cosmos Holdings, Inc. (“Cosmos” or the “Company”) (OTCQB: COSM), an international pharmaceutical company, announced today it agreed to issue 73,334.

  • GlobeNewswire

    Cosmos Holdings, Inc. Completes $500,000 Debt-to-Equity Conversion at $7.50 Per Share

    Cosmos Holdings, Inc. (“Cosmos” or the “Company”) (COSM), an international pharmaceutical company, announced today it agreed to issue 66,667 shares of common stock to Grigorios Siokas, the Company’s CEO, in exchange for the repayment of $500,000 of loans due to Mr. Siokas. The effective conversion rate is $7.50 per share, 117% higher than the $3.45 closing share price of Cosmos on May 29, 2019. Following the conversion of the loans, Cosmos will have a total of 13,154,145 shares of common stock outstanding.

  • GlobeNewswire

    Cosmos Holdings, Inc. Announces Year End 2018 Financial Results

    CHICAGO, April 23, 2019 -- Cosmos Holdings, Inc. ("the Company") (OTCQB: COSM), an international pharmaceutical company, announced its full-year 2018 financial results for the.

  • GlobeNewswire

    Cosmos Holdings, Inc. Adds to Its Advisory Board

    Cosmos Holdings, Inc. ("the Company") (COSM), an international pharmaceutical company, announced that it has added executive Vassos Efthymiadis to its advisory board.  Mr. Efthymiadis is the Managing Director of K&N Efthymiadis S.A. and Vice President of the Redestos Agrotechnology Group, both companies are leaders in agribusiness in Greece.  Mr. Efthymiadis is also President of the Hellenic Crop Protection Association, Board Member of the Hellenic Association of Chemical Industries, and Advisory Board Member of the International Hellenic University.

  • GlobeNewswire

    Cosmos Holdings, Inc. Pays Off All Convertible Debt

    CHICAGO, Feb. 06, 2019 -- Cosmos Holdings, Inc. (OTCQB: COSM), an international pharmaceutical company, announced today that it paid off the remaining balance of its.

  • GlobeNewswire

    Cosmos Holdings, Inc. Adds Distinguished Portfolio Manager With Mid-Cap & Large-Cap Value Expertise to Its Advisory Board

    Cosmos Holdings, Inc. ("the Company") (COSM), an international pharmaceutical company, announced that it has added Tom Kolefas to its Advisory Board. “Tom Kolefas brings a wealth of expertise to our company,” said Grigorios Siokas, Chief Executive Officer of Cosmos Holdings.

  • GlobeNewswire

    Cosmos Holdings, Inc. Acquires Cosmofarm Ltd.

    CHICAGO, Dec. 21, 2018 -- Cosmos Holdings, Inc. (OTCQB: COSM), an international pharmaceutical company, announced the closing of its acquisition of Cosmofarm Ltd (“Cosmofarm”),.

  • GlobeNewswire

    Cosmos Holdings, Inc. Welcomes Dr. Ioannis Dedes MD to Its Advisory Board

    CHICAGO, Nov. 28, 2018 -- Cosmos Holdings, Inc. ("the Company") (OTCQB: COSM), an international pharmaceutical company, announced that it has added to its advisory board - Dr..

  • GlobeNewswire

    Cosmos Holdings, Inc. Adds Distinguished Member to Its Advisory Board to Fuel International Growth

    Cosmos Holdings, Inc. ("the Company") (COSM), an international pharmaceutical company, announced that it has added a new member to its advisory board.  Mr. Anastasios Tzikas is the president of several organizations including: Thessaloniki International Fair HELEXPO SA, Federation of Hellenic Information Technology & Communications (SEPE), and Technopolis Thessaloniki ICT Business Park. “Anastasios Tzikas brings a wealth of expertise and experience to our company,” said Grigorios Siokas, Chief Executive Officer of Cosmos Holdings.

  • GlobeNewswire

    Cosmos Holdings, Inc. Announces Q3 Fiscal Year 2018 Financial and Operating Results

    Cosmos Holdings, Inc. ("the Company") (COSM), an international pharmaceutical company, announced consolidated financial results for the quarter ended and nine-months ended September 30, 2018. Operating revenues were $29.3 million for the nine months ended September 30, 2018, a 48% increase, as compared to $19.8 million for the same period the prior year. For the three months ended September 30, 2018, the gross profit margin increased to 9.3% from 8.1% for the same period in 2017.